Document is current
Any future updates will be listed below
-
Authors
Lewis, Jo Edward https://orcid.org/0000-0002-5722-6778
Montaner, Mireia https://orcid.org/0009-0007-4232-482X
Nuzzaci, Danae
James-Okoro, Paula-Peace
Harada, Norio
Inagaki, Nobuya
Dodson, W. Scott
Knerr, Patrick J.
Douros, Jonathan D.
Gribble, Fiona Mary https://orcid.org/0000-0002-4232-2898
Reimann, Frank https://orcid.org/0000-0001-9399-6377
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MRC_MC_UU_00039/3)
RCUK | Medical Research Council (MRC_MC_UU_00039/5)
RCUK | Medical Research Council (MRC_MC_UU_00039/3)
RCUK | Medical Research Council (MRC_MC_UU_00039/5)
Wellcome Trust (220271/Z/20/Z)
Wellcome Trust (226800/Z/22/Z)
Wellcome Trust (220271/Z/20/Z)
Wellcome Trust (226800/Z/22/Z)
- License Information
-
More Information
Article History
Received: 6 October 2025
Accepted: 22 June 2026
First Online: 24 July 2026
Ethics
Competing interests: F.M.G. is a consultant for Antag and Roche. The Gribble-Reimann laboratory currently hosts projects that receive funding from AstraZeneca and has previously received funding from Eli Lilly and Company. F.M.G. and F.R. received sponsorship to host the European Incretin Study Group meeting (2024) from AstraZeneca, Eli Lilly, Mercodia and Sun Pharma. J.D.D., P.J.K. and W.S.D. are cofounders and shareholders in Volari Therapeutics. J.D.D. and P.J.K. receive research funding from Eli Lilly and Company that is unrelated to this work. The other authors declare no competing interests.
